Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup study

Neyssa M. Marina, Barbara Cushing, Roger Giller, Lewis Cohen, Stephen J. Lauer, Arthur Ablin, Robert Weetman, John Cullen, Paul Rogers, Charles Vinocur, Charles Stolar, Frederick Rescorla, Edith Hawkins, Stephen Heifetz, Pejaver V. Rao, Mark Krailo, Robert P. Castleberry

Research output: Contribution to journalArticle

176 Citations (Scopus)

Abstract

Purpose: To determine whether the 3-year event-free survival (EFS) of children with completely resected immature teratomas is greater than 85%. Patients and Methods: Patients with immature teratomas treated at Pediatric Oncology Group or Children's Cancer Group institutions were eligible. Pathology was centrally reviewed to confirm diagnosis and tumor grading. Follow-up included physical examination, measurement of tumor markers (alpha fetopratein and human chorionic gonadotropin), and imaging. All patients were monitored for events, defined as tumor recurrence, second malignancy, or death. Results: Seventy-three children (median age, 7.8 years) with extracranial immature teratomas were enrolled on study. Primary tumor sites included ovarian (n = 44), testicular (n = 7), and extragonadal (n = 22). However, on review, 23 patients had foci of yolk sac tumor (n = 21) or primitive neuroectodermal tumor (n = 2), whereas 50 had pure immature teratomas. Twenty-five patients had increased alpha fetoprotein (n = 18), human chorionic gonadotropin (n = 5), or both (n = 2); nine had foci of yolk sac tumor on review. Pathology review identified 23 patients with grade 1, 29 with grade 2, and 21 with grade 3 immature teratomas. With a median follow- up of 35 months, the overall 3-year EFS was 93% (95% confidence interval, 86% to 98%), with 3-year EFS of 97.8%, 100%, and 80% for patients with ovarian, testicular, and extragonadal tumors, respectively. Only four of 23 patients with immature teratoma and malignant loci developed recurrence, suggesting that surgical resection followed by close observation are effective treatment. Overall, five patients had disease recurrence 4 to 7 months from diagnosis, and four (80%) are disease free after platinum-based therapy. The fifth patient has residual tumor after cisplatin, etoposide, and bleomycin treatment requiring further therapy. Conclusion: Surgical excision is safe and effective treatment for 80% to 100% of children with immature teratoma.

Original languageEnglish (US)
Pages (from-to)2137-2143
Number of pages7
JournalJournal of Clinical Oncology
Volume17
Issue number7
StatePublished - Jul 1999
Externally publishedYes

Fingerprint

Teratoma
Pediatrics
Neoplasms
Endodermal Sinus Tumor
Disease-Free Survival
Therapeutics
Chorionic Gonadotropin
Recurrence
Alpha Subunit Glycoprotein Hormones
Pathology
Primitive Neuroectodermal Tumors
Second Primary Neoplasms
Neoplasm Grading
Bleomycin
Testicular Neoplasms
Residual Neoplasm
alpha-Fetoproteins
Etoposide
Tumor Biomarkers
Platinum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements : A Pediatric Oncology Group/Children's Cancer Group Intergroup study. / Marina, Neyssa M.; Cushing, Barbara; Giller, Roger; Cohen, Lewis; Lauer, Stephen J.; Ablin, Arthur; Weetman, Robert; Cullen, John; Rogers, Paul; Vinocur, Charles; Stolar, Charles; Rescorla, Frederick; Hawkins, Edith; Heifetz, Stephen; Rao, Pejaver V.; Krailo, Mark; Castleberry, Robert P.

In: Journal of Clinical Oncology, Vol. 17, No. 7, 07.1999, p. 2137-2143.

Research output: Contribution to journalArticle

Marina, NM, Cushing, B, Giller, R, Cohen, L, Lauer, SJ, Ablin, A, Weetman, R, Cullen, J, Rogers, P, Vinocur, C, Stolar, C, Rescorla, F, Hawkins, E, Heifetz, S, Rao, PV, Krailo, M & Castleberry, RP 1999, 'Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup study', Journal of Clinical Oncology, vol. 17, no. 7, pp. 2137-2143.
Marina, Neyssa M. ; Cushing, Barbara ; Giller, Roger ; Cohen, Lewis ; Lauer, Stephen J. ; Ablin, Arthur ; Weetman, Robert ; Cullen, John ; Rogers, Paul ; Vinocur, Charles ; Stolar, Charles ; Rescorla, Frederick ; Hawkins, Edith ; Heifetz, Stephen ; Rao, Pejaver V. ; Krailo, Mark ; Castleberry, Robert P. / Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements : A Pediatric Oncology Group/Children's Cancer Group Intergroup study. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 7. pp. 2137-2143.
@article{1e83d99e0ce345a4a2e5328037c221f3,
title = "Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup study",
abstract = "Purpose: To determine whether the 3-year event-free survival (EFS) of children with completely resected immature teratomas is greater than 85{\%}. Patients and Methods: Patients with immature teratomas treated at Pediatric Oncology Group or Children's Cancer Group institutions were eligible. Pathology was centrally reviewed to confirm diagnosis and tumor grading. Follow-up included physical examination, measurement of tumor markers (alpha fetopratein and human chorionic gonadotropin), and imaging. All patients were monitored for events, defined as tumor recurrence, second malignancy, or death. Results: Seventy-three children (median age, 7.8 years) with extracranial immature teratomas were enrolled on study. Primary tumor sites included ovarian (n = 44), testicular (n = 7), and extragonadal (n = 22). However, on review, 23 patients had foci of yolk sac tumor (n = 21) or primitive neuroectodermal tumor (n = 2), whereas 50 had pure immature teratomas. Twenty-five patients had increased alpha fetoprotein (n = 18), human chorionic gonadotropin (n = 5), or both (n = 2); nine had foci of yolk sac tumor on review. Pathology review identified 23 patients with grade 1, 29 with grade 2, and 21 with grade 3 immature teratomas. With a median follow- up of 35 months, the overall 3-year EFS was 93{\%} (95{\%} confidence interval, 86{\%} to 98{\%}), with 3-year EFS of 97.8{\%}, 100{\%}, and 80{\%} for patients with ovarian, testicular, and extragonadal tumors, respectively. Only four of 23 patients with immature teratoma and malignant loci developed recurrence, suggesting that surgical resection followed by close observation are effective treatment. Overall, five patients had disease recurrence 4 to 7 months from diagnosis, and four (80{\%}) are disease free after platinum-based therapy. The fifth patient has residual tumor after cisplatin, etoposide, and bleomycin treatment requiring further therapy. Conclusion: Surgical excision is safe and effective treatment for 80{\%} to 100{\%} of children with immature teratoma.",
author = "Marina, {Neyssa M.} and Barbara Cushing and Roger Giller and Lewis Cohen and Lauer, {Stephen J.} and Arthur Ablin and Robert Weetman and John Cullen and Paul Rogers and Charles Vinocur and Charles Stolar and Frederick Rescorla and Edith Hawkins and Stephen Heifetz and Rao, {Pejaver V.} and Mark Krailo and Castleberry, {Robert P.}",
year = "1999",
month = "7",
language = "English (US)",
volume = "17",
pages = "2137--2143",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements

T2 - A Pediatric Oncology Group/Children's Cancer Group Intergroup study

AU - Marina, Neyssa M.

AU - Cushing, Barbara

AU - Giller, Roger

AU - Cohen, Lewis

AU - Lauer, Stephen J.

AU - Ablin, Arthur

AU - Weetman, Robert

AU - Cullen, John

AU - Rogers, Paul

AU - Vinocur, Charles

AU - Stolar, Charles

AU - Rescorla, Frederick

AU - Hawkins, Edith

AU - Heifetz, Stephen

AU - Rao, Pejaver V.

AU - Krailo, Mark

AU - Castleberry, Robert P.

PY - 1999/7

Y1 - 1999/7

N2 - Purpose: To determine whether the 3-year event-free survival (EFS) of children with completely resected immature teratomas is greater than 85%. Patients and Methods: Patients with immature teratomas treated at Pediatric Oncology Group or Children's Cancer Group institutions were eligible. Pathology was centrally reviewed to confirm diagnosis and tumor grading. Follow-up included physical examination, measurement of tumor markers (alpha fetopratein and human chorionic gonadotropin), and imaging. All patients were monitored for events, defined as tumor recurrence, second malignancy, or death. Results: Seventy-three children (median age, 7.8 years) with extracranial immature teratomas were enrolled on study. Primary tumor sites included ovarian (n = 44), testicular (n = 7), and extragonadal (n = 22). However, on review, 23 patients had foci of yolk sac tumor (n = 21) or primitive neuroectodermal tumor (n = 2), whereas 50 had pure immature teratomas. Twenty-five patients had increased alpha fetoprotein (n = 18), human chorionic gonadotropin (n = 5), or both (n = 2); nine had foci of yolk sac tumor on review. Pathology review identified 23 patients with grade 1, 29 with grade 2, and 21 with grade 3 immature teratomas. With a median follow- up of 35 months, the overall 3-year EFS was 93% (95% confidence interval, 86% to 98%), with 3-year EFS of 97.8%, 100%, and 80% for patients with ovarian, testicular, and extragonadal tumors, respectively. Only four of 23 patients with immature teratoma and malignant loci developed recurrence, suggesting that surgical resection followed by close observation are effective treatment. Overall, five patients had disease recurrence 4 to 7 months from diagnosis, and four (80%) are disease free after platinum-based therapy. The fifth patient has residual tumor after cisplatin, etoposide, and bleomycin treatment requiring further therapy. Conclusion: Surgical excision is safe and effective treatment for 80% to 100% of children with immature teratoma.

AB - Purpose: To determine whether the 3-year event-free survival (EFS) of children with completely resected immature teratomas is greater than 85%. Patients and Methods: Patients with immature teratomas treated at Pediatric Oncology Group or Children's Cancer Group institutions were eligible. Pathology was centrally reviewed to confirm diagnosis and tumor grading. Follow-up included physical examination, measurement of tumor markers (alpha fetopratein and human chorionic gonadotropin), and imaging. All patients were monitored for events, defined as tumor recurrence, second malignancy, or death. Results: Seventy-three children (median age, 7.8 years) with extracranial immature teratomas were enrolled on study. Primary tumor sites included ovarian (n = 44), testicular (n = 7), and extragonadal (n = 22). However, on review, 23 patients had foci of yolk sac tumor (n = 21) or primitive neuroectodermal tumor (n = 2), whereas 50 had pure immature teratomas. Twenty-five patients had increased alpha fetoprotein (n = 18), human chorionic gonadotropin (n = 5), or both (n = 2); nine had foci of yolk sac tumor on review. Pathology review identified 23 patients with grade 1, 29 with grade 2, and 21 with grade 3 immature teratomas. With a median follow- up of 35 months, the overall 3-year EFS was 93% (95% confidence interval, 86% to 98%), with 3-year EFS of 97.8%, 100%, and 80% for patients with ovarian, testicular, and extragonadal tumors, respectively. Only four of 23 patients with immature teratoma and malignant loci developed recurrence, suggesting that surgical resection followed by close observation are effective treatment. Overall, five patients had disease recurrence 4 to 7 months from diagnosis, and four (80%) are disease free after platinum-based therapy. The fifth patient has residual tumor after cisplatin, etoposide, and bleomycin treatment requiring further therapy. Conclusion: Surgical excision is safe and effective treatment for 80% to 100% of children with immature teratoma.

UR - http://www.scopus.com/inward/record.url?scp=0033026227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033026227&partnerID=8YFLogxK

M3 - Article

C2 - 10561269

AN - SCOPUS:0033026227

VL - 17

SP - 2137

EP - 2143

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -